PerkinElmer
In Brief This Week: T2 Biosystems, Novacyt, OpGen, Dante Genomics, Nautilus Biotechnology, More
News items for the week of Jan. 23, 2023.
PerkinElmer Becoming Pure Play Dx, Life Science Firm, Spurred on by COVID Innovations
At the JP Morgan conference, the firm's CEO said that it chose to divest its applied, food, and enterprise businesses due to innovations it achieved during the pandemic.
State labs and commercial companies see rising spinal muscular atrophy test volumes as screening programs launch in US states and European countries, among others.
Cowen Upgrades PerkinElmer Stock to Outperform
Analyst Max Masucci said the firm is expected to generate at least $3.21 billion in COVID-19-related revenues, while he lowered the stock price target to $164 per share.
In Brief This Week: 908 Devices, Natera, PerkinElmer, Hologic, Hamilton, BioFluidiX, More
News items for the week of Nov. 14, 2022
Oct 20, 2022
Apr 21, 2022
Apr 6, 2022